Sign in
IMTX Stock Price, Chart, Stats & News
Immatics N.V.
Save
1.24B
Market cap
–
Current P/E
–
Forward P/E
IMTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -371.64% |
Pretax margin | -394.90% |
Net margin | -390.94% |
Effective tax rate | 1.00% |
ROA | -33.57% |
ROE | -39.69% |
D/E | 0.03x |
Interest coverage ratio | -197.41x |
IMTX valuation
P/E | – |
P/S | 22.56x |
P/B | 2.12x |
P/CF | -5.83x |
P/FCF | -5.97x |
P/OCF | -5.83x |
PEG | 0.07x |
EV multiple | -7.36x |
About
Immatics N. V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Similar securities
Based on sector and market capitalization
Report issue